Physiomics (GB:PYC) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Physiomics plc, a leader in mathematical modelling, has secured a £157k contract with a major pharmaceutical client to enhance dosing and scheduling decisions for a novel cancer therapy. This project marks the company’s first use of Antibody-Drug Conjugates in their Virtual Tumour platform, positioning Physiomics at the cutting edge of oncology drug development. The collaboration underscores the ongoing trust in Physiomics’ expertise in advanced therapeutic modelling.
For further insights into GB:PYC stock, check out TipRanks’ Stock Analysis page.
